Vitarka Therapeutics
Targeting the undruggable
* Data source: Crunchbase
- Founded
- 2021
- Employees*
- 2-10
- Funding to Date*
- $875,000
- Website
- www.vitarka.co.uk
"Vitarka is revolutionizing intracellular drug delivery by developing a new tumor-targeted platform technology using pore-forming proteins. RNA therapeutics have the potential to target 90% of the druggable proteome and bring benefits to patients and their families."
Almost 85% patients with late-stage cancers do not have treatment options.
Vitarka Therapeutics is a pre-clinical stage biotech focused on developing RNAi therapies using a proprietary non-viral delivery platform. The underlying technology utilizes pore-forming proteins for targeted, cytosolic delivery of RNA therapeutics. Vitarka Therapeutics believes it can unlock new targeted therapeutic approaches for cancer treatment.
More Companies
